Body composition, soluble markers of inflammation, and bone mineral density in antiretroviral therapy-naive HIV-1-infected individuals
about
Dysregulated B cell expression of RANKL and OPG correlates with loss of bone mineral density in HIV infectionAssociation of Blood Biomarkers of Bone Turnover in HIV-1 Infected Individuals Receiving Anti-Retroviral Therapy (ART)Prevalence of and risk factors for low bone mineral density in untreated HIV infection: a substudy of the INSIGHT Strategic Timing of AntiRetroviral Treatment (START) trial.Is bone loss linked to chronic inflammation in antiretroviral-naive HIV-infected adults? A 48-week matched cohort study.Higher Levels of Osteoprotegerin and Immune Activation/Immunosenescence Markers Are Correlated with Concomitant Bone and Endovascular Damage in HIV-Suppressed Patients.Changes in Inflammation and Immune Activation With Atazanavir-, Raltegravir-, Darunavir-Based Initial Antiviral Therapy: ACTG 5260s.Structural Bone Deficits in HIV/HCV-Coinfected, HCV-Monoinfected, and HIV-Monoinfected WomenIncreased risk of hip fracture associated with dually treated HIV/hepatitis B virus coinfectionSerum adiponectin in HIV-1 and hepatitis C virus mono- and co-infected Kenyan injection drug users.Changes in Bone Mineral Density After Initiation of Antiretroviral Treatment With Tenofovir Disoproxil Fumarate/Emtricitabine Plus Atazanavir/Ritonavir, Darunavir/Ritonavir, or Raltegravir.Osteoprotegerin, but Not Receptor Activator for Nuclear Factor-κB Ligand, is Associated With Subclinical Coronary Atherosclerosis in HIV-Infected MenBone loss in HIV: a contemporary review.Bone Disease in HIV: Recommendations for Screening and Management in the Older Patient.Hepatitis C virus coinfection as a risk factor for osteoporosis and fracture.Physiological and pathophysiological bone turnover - role of the immune system.Changes in abdominal fat following antiretroviral therapy initiation in HIV-infected individuals correlate with waist circumference and self-reported changes.Oxidized lipoproteins are associated with markers of inflammation and immune activation in HIV-1 infection.Immediate Initiation of Antiretroviral Therapy for HIV Infection Accelerates Bone Loss Relative to Deferring Therapy: Findings from the START Bone Mineral Density Substudy, a Randomized Trial.Brief Report: Macrophage Activation in HIV-Infected Adolescent Males Contributes to Differential Bone Loss by Sex: Adolescent Trials Network Study 021Changes in plasma RANKL-osteoprotegerin in a Prospective, Randomized Clinical trial of Initial Antiviral Therapy: A5260s.
P2860
Q34506677-853F3EC4-0053-4F29-8377-C91210DBA014Q35096244-442EADD5-A21F-4E18-A241-2CEE3A2ACD47Q35124970-86C2505D-5641-4159-ACA1-F2E7CC895E16Q35505203-D22FD805-23A2-4F6E-9F3B-D9DAC63A8505Q35935297-2FD25634-2A8E-4F78-A1CA-7E1226CCA376Q35974422-E361435E-6687-47BC-A934-B23330C60B3AQ35993503-3A10CD5C-BB21-44F3-8E61-F14CF4D89A09Q36031673-42C0B153-30B0-4DE1-9D28-06757C5AF1D6Q36051167-A00CE2F2-FDF4-4151-830A-59298D899800Q36078749-093BB139-3AE1-4536-9DE3-9D9A336D98CAQ36219767-F55521C5-3C8A-47C6-828D-8E496409B4F5Q36330955-BD9E7B58-CC5D-40AA-978F-9F82A874BE1AQ38540406-8973B9F1-0A46-4C7D-B274-CACA7BE55755Q38738823-6ABEB017-EFA1-4CFE-800D-6EA1E45BA23FQ38867785-25D4E9C6-CD0A-40AC-8DE3-DA1010846DBDQ38936060-7CC0406E-09CE-48D9-B560-38FFB9501530Q39414284-5704D63C-5389-4E8D-A6FE-EC5F1666C6BCQ40158081-E8AAAF46-D962-4775-8499-8FF22E5120F1Q40788143-A222E5F6-D44A-48C5-82D5-E972246271D1Q54256985-0AF3C611-8071-415B-B403-B57FF728E21E
P2860
Body composition, soluble markers of inflammation, and bone mineral density in antiretroviral therapy-naive HIV-1-infected individuals
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
2013年论文
@zh
2013年论文
@zh-cn
name
Body composition, soluble mark ...... ive HIV-1-infected individuals
@en
type
label
Body composition, soluble mark ...... ive HIV-1-infected individuals
@en
prefLabel
Body composition, soluble mark ...... ive HIV-1-infected individuals
@en
P2093
P2860
P1476
Body composition, soluble mark ...... ive HIV-1-infected individuals
@en
P2093
Grace A McComsey
Heather J Ribaudo
Jennifer Rothenberg
Judith S Currier
Michael P Dubé
Todd T Brown
P2860
P304
P356
10.1097/QAI.0B013E318295EB1D
P407
P577
2013-07-01T00:00:00Z